Breaking News Instant updates and real-time market news.

CMTL

Comtech

$20.64 /

+0.09 (+0.44%)

, ACTG

Acacia Research

$4.33 /

-0.01 (-0.23%)

 08:49
01/25/22
 01/25
08:49
 01/25/22
08:49

Comtech board rejects Acacia Research proposal to acquire the company

Comtech (CMTL) announced that the company's board of directors has unanimously rejected the unsolicited proposal to acquire Comtech received from Acacia Research (ACTG) on October 29, 2021. The Comtech board of directors, including the recently appointed members, carefully evaluated the proposal in consultation with the board's independent advisors and determined that the proposal undervalues the company and is not in the best interests of Comtech's shareholders. The company said, "The Comtech Board's unanimous conclusion regarding the inadequacy of Acacia's proposal is based on the following key considerations: Comtech has made strategic investments in innovative technologies that position the Company to capitalize on large, long-term renewal cycles in the 911 public safety and satellite and space communication markets. Structural changes in these markets are expected to drive significant long-term growth driven by multi-year investment cycles that are well-aligned with Comtech's core capabilities, products, and services. Comtech is already beginning to see the long-term benefits of these investments and end market trends, which have created a number of large-scale opportunities being pursued by the Company. As such, the Company's Board and management remain highly confident in Comtech's long-term business outlook and believe the Company is well positioned to create significant value for its shareholders. Based on the foregoing considerations, among others, the Board unanimously determined that the non-binding Acacia proposal grossly undervalues the Company, does not reflect the transformational changes underway in the Company's end-markets and the significant inherent value in the Company's plan, and, thus, is not in the best interests of the Company and its shareholders."

CMTL

Comtech

$20.64 /

+0.09 (+0.44%)

 ACTG

Acacia Research

$4.33 /

-0.01 (-0.23%)

OTHER BREAKING NEWS FROM THE FLY

Upgrade
Elior Group upgraded to Hold from Sell at Stifel » 04:59
12/06/22
12/06
04:59
12/06/22
04:59
ELROF

Elior Group

$2.85 /

+ (+0.00%)

Stifel analyst Simon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ELROF Elior Group
$2.85 /

+ (+0.00%)

11/14/22 Barclays
Elior Group downgraded to Underweight from Equal Weight at Barclays
11/11/22 UBS
Elior Group price target lowered to EUR 3 from EUR 3.30 at UBS
10/05/22 Deutsche Bank
Elior Group price target lowered to EUR 2.20 from EUR 2.50 at Deutsche Bank
09/26/22 JPMorgan
Elior Group price target lowered to EUR 2 from EUR 2.50 at JPMorgan
Downgrade
Bankinter downgraded to Underweight from Neutral at JPMorgan » 04:57
12/06/22
12/06
04:57
12/06/22
04:57
BKIMF

Bankinter

$6.50 /

+ (+0.00%)

JPMorgan analyst Sofie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BKIMF Bankinter
$6.50 /

+ (+0.00%)

10/24/22 Berenberg
Bankinter price target raised to EUR 7 from EUR 5.70 at Berenberg
10/21/22 JPMorgan
Bankinter price target raised to EUR 5.60 from EUR 5.50 at JPMorgan
10/21/22 Societe Generale
Bankinter price target raised to EUR 6 from EUR 5.90 at Societe Generale
10/18/22 Deutsche Bank
Bankinter price target lowered to EUR 5.95 from EUR 6.05 at Deutsche Bank
Downgrade
Societe Generale downgraded to Neutral from Overweight at JPMorgan » 04:56
12/06/22
12/06
04:56
12/06/22
04:56
SCGLY

Societe Generale

$4.75 /

-0.12 (-2.46%)

JPMorgan analyst Kian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SCGLY Societe Generale
$4.75 /

-0.12 (-2.46%)

11/22/22
AllianceBernstein, Societe Generale to form cash equities JV
09/30/22
Societe Generale board picks Slawomir Krupa as next CEO
06/07/22
FIS delivers derivatives solution to Societe Generale
SCGLY Societe Generale
$4.75 /

-0.12 (-2.46%)

11/18/22 Morgan Stanley
Societe Generale downgraded to Equal Weight from Overweight at Morgan Stanley
11/07/22 JPMorgan
Societe Generale price target lowered to EUR 33 from EUR 34 at JPMorgan
11/07/22 Deutsche Bank
Societe Generale price target raised to EUR 37 from EUR 34 at Deutsche Bank
11/02/22 Barclays
Societe Generale price target lowered to EUR 40 from EUR 42.30 at Barclays
SCGLY Societe Generale
$4.75 /

-0.12 (-2.46%)

09/30/22
Societe Generale IB head emerging as favorite to replace CEO, Bloomberg says
07/07/22
VW selects more banks to underwrite Porsche unit IPO, Bloomberg says
SCGLY Societe Generale
$4.75 /

-0.12 (-2.46%)

09/01/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Conference/Events
Fiverr management to meet with Piper Sandler » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
FVRR

Fiverr

$32.28 /

-1.585 (-4.68%)

Meeting to be held in San…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FVRR Fiverr
$32.28 /

-1.585 (-4.68%)

11/09/22
Fiverr rises 11.8%
08/30/22
Fiverr announces partnership with Shutterstock
08/11/22
Fiverr partners with Selina to bring together 'Anywhere Workers'
08/04/22
Fiverr rises 13.0%
FVRR Fiverr
$32.28 /

-1.585 (-4.68%)

11/10/22 Oppenheimer
Fiverr price target lowered to $40 from $50 at Oppenheimer
11/09/22 Piper Sandler
Fiverr margin expansion story 'very much on track,' says Piper Sandler
08/05/22 Needham
Fiverr price target raised to $50 from $40 at Needham
08/04/22 Piper Sandler
Piper Sandler applauds strategic pivot at Fiverr, keeps $50 target
FVRR Fiverr
$32.28 /

-1.585 (-4.68%)

11/09/22
Fiverr narrows FY22 revenue $334M-$340M from $332M-$340M, consensus $336.86M
11/09/22
Fiverr sees Q4 revenue $79.8M-$85.8M, consensus $83.99M
11/09/22
Fiverr reports Q3 EPS 21c, consensus 14c
08/04/22
Fiverr cuts FY22 revenue view to $332M-$340M from $345M-$365M
FVRR Fiverr
$32.28 /

-1.585 (-4.68%)

07/26/22
Fiverr laying off 60 employees, or 8% of workforce, Globes reports
00:00 Today
Fiverr
Conference/Events
Truist leisure/lodging analyst holds an analyst/industry conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55

Lodging & Leisure…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
PlayAGS management to meet with B. Riley » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
AGS

PlayAGS

$5.23 /

-0.13 (-2.43%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AGS PlayAGS
$5.23 /

-0.13 (-2.43%)

11/15/22
PlayAGS falls -16.6%
11/15/22
PlayAGS falls -17.0%
11/15/22
PlayAGS falls -16.5%
11/08/22
PlayAGS says 'on pace' to deliver net leverage target of less than 4.0 times
AGS PlayAGS
$5.23 /

-0.13 (-2.43%)

08/09/22 B. Riley
PlayAGS price target raised to $14 from $12 at B. Riley
08/01/22 Stifel
PlayAGS price target lowered to $9 from $11 at Stifel
07/20/22 Truist
PlayAGS price target lowered to $12 from $13 at Truist
07/14/22 Deutsche Bank
PlayAGS price target lowered to $11 from $12 at Deutsche Bank
AGS PlayAGS
$5.23 /

-0.13 (-2.43%)

11/08/22
PlayAGS reports Q3 EPS 1c, consensus 0c
08/08/22
PlayAGS reports Q2 EPS 4c, consensus (3c)
  • 15
    Nov
AGS PlayAGS
$5.23 /

-0.13 (-2.43%)

08/12/22
Inspired offers to buy PlayAGS for $10 per share in cash, Reuters says
08/12/22
Inspired Entertainment bidding to buy PlayAGS, Reuters reports
AGS PlayAGS
$5.23 /

-0.13 (-2.43%)

08/15/22
What You Missed On Wall Street On Monday
08/15/22
What You Missed On Wall Street This Morning
08/15/22
Fly Intel: Pre-market Movers
08/12/22
What You Missed On Wall Street On Friday
00:00 Today
PlayAGS
Conference/Events
LKQ Corp. management to meet with Barrington » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
LKQ

LKQ Corp.

$53.97 /

-1.07 (-1.94%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LKQ LKQ Corp.
$53.97 /

-1.07 (-1.94%)

10/27/22
LKQ Corp. raises dividend 10%, raises share repurchase plan by $1B
09/19/22
LKQ Corp. appoints Varun Laroyia as CEO, LKQ Europe, Rick Galloway as CFO
LKQ LKQ Corp.
$53.97 /

-1.07 (-1.94%)

07/12/22 MKM Partners
LKQ Corp. initiated with a Buy at MKM Partners
04/28/22 Barrington
LKQ Corp. upgraded to Outperform at Barrington after beat and raise report
04/28/22 Barrington
LKQ Corp. upgraded to Outperform from Market Perform at Barrington
04/11/22 Raymond James
LKQ Corp. price target lowered to $59 from $62 at Raymond James
LKQ LKQ Corp.
$53.97 /

-1.07 (-1.94%)

10/27/22
LKQ Corp. narrows FY22 adjusted EPS view to $3.85-$3.95 from $3.85-$4.05
10/27/22
LKQ Corp. reports Q3 adjusted EPS 97c, consensus 96c
07/28/22
LKQ Corp. narrows FY22 adjusted EPS view to $3.85-$4.05 from $3.80-$4.10
07/28/22
LKQ Corp. reports Q2 adjusted EPS $1.09, consensus $1.02
02/23/23
LKQ Corp. - LKQ
00:00 Today
LKQ Corp.
Conference/Events
Newmark management to meet with Piper Sandler » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
NMRK

Newmark

$8.48 /

-0.135 (-1.57%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NMRK Newmark
$8.48 /

-0.135 (-1.57%)

10/06/22
Newmark names Angie Leccese as chief marketing officer
08/15/22
Paulson buys VMware, exits DiDi in Q2
NMRK Newmark
$8.48 /

-0.135 (-1.57%)

10/07/22 Piper Sandler
Newmark price target lowered to $10 from $12 at Piper Sandler
04/18/22 Piper Sandler
Newmark downgraded to Neutral from Overweight at Piper Sandler
04/05/22 Goldman Sachs
Newmark initiated with a Neutral at Goldman Sachs
03/10/22 Wolfe Research
Newmark downgraded to Peer Perform from Outperform at Wolfe Research
NMRK Newmark
$8.48 /

-0.135 (-1.57%)

10/28/22
Newmark lowers FY22 revenue view to $2.7B-$2.8B from $3.0B-$3.1B
10/28/22
Newmark reports Q3 adjusted EPS 35c, consensus 40c
07/29/22
Newmark reaffirms FY22 revenue view $3.000B-$3.100B, consensus $3.06B
07/29/22
Newmark reports Q2 GAAP EPS 26c, consensus 36c
NMRK Newmark
$8.48 /

-0.135 (-1.57%)

10/28/22
What You Missed On Wall Street This Morning
00:00 Today
Newmark
12/07/22
Newmark
Conference/Events
Matson management to meet virtually with Stephens » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
MATX

Matson

$61.60 /

-2.89 (-4.48%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
MATX Matson
$61.60 /

-2.89 (-4.48%)

08/23/22
Matson adds 3M shares to repurchase program
08/02/22
Matson falls -9.7%
06/22/22
Matson raises quarterly dividend to 31c per share from 30c
MATX Matson
$61.60 /

-2.89 (-4.48%)

11/17/22 Wolfe Research
Wolfe reshuffles ratings in freight with five downgrades and one upgrade
11/17/22 Wolfe Research
Matson upgraded to Peer Perform from Underperform at Wolfe Research
10/20/22 Stifel
Matson price target lowered to $81 from $93 at Stifel
08/16/22 Wolfe Research
Wolfe starts Matson at Underperform, sees 'peak EPS' in 2022
MATX Matson
$61.60 /

-2.89 (-4.48%)

11/02/22
Matson reports Q3 EPS $6.89, consensus $7.07
10/17/22
Matson sees Q3 EPS $6.67-$6.79, consensus $7.28
07/19/22
Matson sees Q2 $9.31-$9.42 vs $3.71 last year
MATX Matson
$61.60 /

-2.89 (-4.48%)

10/17/22
Fly Intel: After-Hours Movers
08/16/22
What You Missed On Wall Street On Tuesday
08/16/22
What You Missed On Wall Street This Morning
08/16/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
00:00 Today
Matson
Conference/Events
Candel Therapeutics to host a virtual research and development day » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
CADL

Candel Therapeutics

$1.97 /

+0.08 (+4.23%)

Virtual Research and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
CADL Candel Therapeutics
$1.97 /

+0.08 (+4.23%)

11/18/22
Candel Therapeutics presents updated data from Phase 1 trial of CAN-3110
11/11/22
Candel Therapeutics presents data on CAN-2409 in combination with nivolumab
10/26/22
Candel Therapeutics partners with Penn to study novel viral immunotherapies
09/15/22
Candel Therapeutics receives orphan drug designation for CAN--2409
CADL Candel Therapeutics
$1.97 /

+0.08 (+4.23%)

12/02/22 H.C. Wainwright
Candel Therapeutics initiated with a Buy at H.C. Wainwright
03/31/22 BMO Capital
Candel Therapeutics price target lowered to $12 from $18 at BMO Capital
CADL Candel Therapeutics
$1.97 /

+0.08 (+4.23%)

11/10/22
Candel Therapeutics reports Q EPS (30c), consensus (35c)
08/05/22
Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year
11:00 Today
Candel Therapeutics
Conference/Events
Editas Medicine to host conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
EDIT

Editas Medicine

$9.83 /

-0.425 (-4.15%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

11/17/22
Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
11/17/22
Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
10/18/22
Editas Medicine rises after report of talks to sell preclinical oncology assets
10/13/22
Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

11/02/22
Editas Medicine reports Q3 EPS (81c), consensus (86c)
08/03/22
Editas Medicine reports Q2 EPS (78c), consensus (82c)
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

10/18/22
Editas in talks to sell preclinical oncology assets, Endpoints News says
07/25/22
Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

11/21/22
Biotech Alert: Searches spiking for these stocks today
11/18/22
What You Missed On Wall Street On Friday
11/18/22
What You Missed On Wall Street This Morning
11/18/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
08:00 Today
Editas Medicine - EDIT
Conference/Events
Century Communities management to meet virtually with BTIG » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
CCS

Century Communities

$49.58 /

-1.54 (-3.01%)

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CCS Century Communities
$49.58 /

-1.54 (-3.01%)

10/27/22
Century Communities falls -12.0%
10/26/22
Century Communities CFO provides FY22 outlook
CCS Century Communities
$49.58 /

-1.54 (-3.01%)

11/29/22 BTIG
Century Communities initiated with a Neutral at BTIG
11/22/22 JPMorgan
Century Communities downgraded to Underweight from Overweight at JPMorgan
10/27/22 B. Riley
Century Communities downgraded on margin headwinds at B. Riley
10/27/22 B. Riley
Century Communities downgraded to Neutral from Buy at B. Riley
CCS Century Communities
$49.58 /

-1.54 (-3.01%)

10/26/22
Century Communities reports Q3 EPS $4.44, consensus $4.20
07/27/22
Century Communities backs FY22 home sales revenue view $4.3B-$4.9B
07/27/22
Century Communities reports Q2 EPS $4.78, consensus $4.46
00:00 Today
Century Communities
Conference/Events
iCAD management to meet virtually with BTIG » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
ICAD

iCAD

$1.74 /

-0.08 (-4.40%)

Medical Technology and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ICAD iCAD
$1.74 /

-0.08 (-4.40%)

11/28/22
iCAD, Google Health enter development, commercialization agreement
11/21/22
iCAD announces new research on Breast AI Suite
10/11/22
iCAD signs new agreement with Solis Mammography
08/29/22
iCAD says growing number of hospitals choos to adopt Breast AI suite
ICAD iCAD
$1.74 /

-0.08 (-4.40%)

11/29/22 Lake Street
Google Health partnership 'significant positive' for iCAD, says Lake Street
11/28/22 JMP Securities
JMP views iCAD agreement with Google Health 'very favorably'
11/11/22 Lake Street
iCAD price target lowered to $5 from $8 at Lake Street
09/01/22 JMP Securities
iCAD price target lowered to $7 from $13 at JMP Securities
ICAD iCAD
$1.74 /

-0.08 (-4.40%)

08/10/22
iCAD reports Q2 EPS (12c), consensus (11c)
00:00 Today
iCAD
Conference/Events
DMC Global management to meet with KeyBanc » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
BOOM

DMC Global

$17.47 /

-1.035 (-5.59%)

Meetings to be held with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BOOM DMC Global
$17.47 /

-1.035 (-5.59%)

09/15/22
DynaEnergetics launches IS2 Xpress upgrade
08/11/22
DMC Global announces planned retirement of CFO Kuta
BOOM DMC Global
$17.47 /

-1.035 (-5.59%)

09/14/22
DMC Global management to meet with Roth Capital
05/03/22 Roth Capital
DMC Global price target lowered to $35 from $50 at Roth Capital
12/23/21 Stifel
DMC Global price target raised to $48 from $46 at Stifel
BOOM DMC Global
$17.47 /

-1.035 (-5.59%)

11/03/22
DMC Global sees Q4 revenue $158M-$168M, consensus $160.01M
11/03/22
DMC Global reports Q3 EPS 46c, consensus 27c
08/04/22
DMC Global sees Q3 consolidated sales $155M-$163M, consensus $155.16M
08/04/22
DMC Global reports Q2 adjusted EPS 29c consensus (6c)
00:00 Today
DMC Global
12/07/22
DMC Global
Conference/Events
Dynatronics management to meet virtually with Lake Street » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
DYNT

Dynatronics

/

+

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DYNT Dynatronics
/

+

07/06/22
Dynatronics appoints Mike Withers as CIO, John Krier to take on CFO duties
07/06/22
Dynatronics: CEO Krier to resume CFO role, Mike Withers joins as CIO
DYNT Dynatronics
/

+

07/27/22 Lake Street
Dynatronics initiated with a Buy at Lake Street
DYNT Dynatronics
/

+

11/10/22
Dynatronics sees 2023 revenue $45M-$48M, consensus $46.34M
11/10/22
Dynatronics reports Q1 EPS (4c), consensus (6c)
11/10/22
Dynatronics backs FY23 revenue view $45M-$48M, consensus $46.34M
11/10/22
Dynatronics reports Q1 EPS (4c), consensus (6c)
DYNT Dynatronics
/

+

07/27/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
00:00 Today
Dynatronics
12/07/22
Dynatronics
Conference/Events
Eagle Pharmaceuticals to host investor day » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
EGRX

Eagle Pharmaceuticals

$33.95 /

-1.9 (-5.30%)

Investor Day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EGRX Eagle Pharmaceuticals
$33.95 /

-1.9 (-5.30%)

11/07/22
Eagle Pharmaceuticals sees FY22 adjusted non-GAAP R&D expense less than $40M
10/12/22
Eagle Pharmaceuticals submits IND application to FDA for CAL02
10/03/22
Eagle Pharmaceuticals, Enalare announce FDA orphan designation for ENA-001
09/27/22
Eagle and Enalare announce $50.3M contract from BARDA to develop ENA-001
EGRX Eagle Pharmaceuticals
$33.95 /

-1.9 (-5.30%)

12/16/21 Barclays
Endo price target lowered to $5 from $7 at Barclays
12/15/21 Cantor Fitzgerald
Vasopressin approval 'a key win' for Eagle Pharmaceuticals, says Cantor
EGRX Eagle Pharmaceuticals
$33.95 /

-1.9 (-5.30%)

11/07/22
Eagle Pharmaceuticals reports Q3 adjusted EPS $1.13, consensus 91c
08/09/22
Eagle sees FY22 Adjusted non-GAAP R&D expense $46M-$50M vs $32.5M last year
08/09/22
Eagle Pharmaceuticals reports Q2 non-GAAP EPS $1.78, consensus $3.36
08:00 Today
Eagle Pharmaceuticals
Conference/Events
JPMorgan transports analyst to hold an analyst/industry conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55

Transports Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

Conference/Events
Celldex to host conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
CLDX

Celldex

$36.70 /

-0.665 (-1.78%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

11/09/22
Celldex sees cash, equivalents sufficient to meet requirements through 2025
07/21/22
Celldex announces first patient dosed in Phase 2 study of barzolvolimab
06/30/22
Celldex presents positive Phase 1b interim data from barzolvolimab
06/21/22
Celldex announces first patient dosed in Phase 2 study of barzolvolimab
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

11/09/22
Celldex reports Q3 EPS (57c), consensus (58c)
08/08/22
Celldex reports Q2 EPS (77c) vs. (34c) last year
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

11/18/22
Sell these stocks now, proven algorithm says
09/16/22
Sell these stocks now, proven algorithm says
08:00 Today
Celldex - CLDX
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

07/12/22
Celldex put volume heavy and directionally bearish
Conference/Events
Alphatec to participate in a conference call with Lake Street » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
ATEC

Alphatec

$9.75 /

-0.525 (-5.11%)

Key Opinion Leader…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ATEC Alphatec
$9.75 /

-0.525 (-5.11%)

10/10/22
Alphatec reports preliminary Q3 revenue $89M-$90M, consensus $81.37M
07/14/22
Alphatec artificially inflated sales, Bonitas says in short report
ATEC Alphatec
$9.75 /

-0.525 (-5.11%)

10/17/22 Lake Street
Alphatec price target raised to $16.50 from $13 at Lake Street
10/12/22 Piper Sandler
CMS proposal a positive for Med Tech sector, says Piper Sandler
10/12/22 Jefferies
Alphatec initiated with a Buy at Jefferies
10/10/22 Piper Sandler
Piper Sandler bullish on Alphatec following Q3 preliminary results
ATEC Alphatec
$9.75 /

-0.525 (-5.11%)

11/03/22
Alphatec sees FY22 revenue $340M, consensus $328.2M
11/03/22
Alphatec reports Q3 EPS (35c), consensus (30c)
08/04/22
Alphatec raises FY22 revenue view to $325M, consensus $316.7M
08/04/22
Alphatec reports Q2 EPS (36c), consensus (29c)
ATEC Alphatec
$9.75 /

-0.525 (-5.11%)

07/14/22
Bonitas Research reports short position in Alphatec
ATEC Alphatec
$9.75 /

-0.525 (-5.11%)

10/10/22
What You Missed On Wall Street On Monday
10/10/22
What You Missed On Wall Street This Morning
07/14/22
What You Missed On Wall Street On Thursday
07/14/22
What You Missed On Wall Street This Morning
14:00 Today
Alphatec - ATEC
Conference/Events
JPMorgan transportation/fuel analyst holds analyst/industry conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55

Transportation/Fuel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial
Conference/Events
BTIG medical technology analyst to hold a group dinner » 04:55
12/06/22
12/06
04:55
12/06/22
04:55

Medical Tech &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
BTIG policy director to hold an analyst/industry conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55

Policy Research Director…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Janus International Group management to meet with KeyBanc » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
JBI

Janus International Group

$10.75 /

-0.09 (-0.83%)

Meetings to be held with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JBI Janus International Group
$10.75 /

-0.09 (-0.83%)

09/26/22
Janus International Group appoints Elliot Kahler as general counsel
06/21/22
Janus International Group appoints Anselm Wong as CFO, effective July 1
JBI Janus International Group
$10.75 /

-0.09 (-0.83%)

09/06/22 CJS Securities
Janus International Group initiated with an Outperform at CJS Securities
01/26/22 Benchmark
Janus International Group initiated with a Buy at Benchmark
12/08/21 Stifel
Janus International Group initiated with a Buy at Stifel
12/07/21 UBS
Janus International Group initiated with a Neutral at UBS
JBI Janus International Group
$10.75 /

-0.09 (-0.83%)

11/10/22
Janus International Group ups FY22 revenue view to $990M-$1.01B from $940M-$960M
11/10/22
Janus International Group reports Q3 adjusted EPS 22c consensus 17c
08/16/22
Janus International Group reports Q2 EPS 17c, consensus 13c
06/21/22
Janus International Group backs FY22 revenue view $890M-$910M, consensus $908M
JBI Janus International Group
$10.75 /

-0.09 (-0.83%)

06/21/22
What You Missed On Wall Street On Tuesday
06/21/22
What You Missed On Wall Street This Morning
00:00 Today
Janus International Group
12/07/22
Janus International Group
Conference/Events
Comscore management to meet with Needham » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
SCOR

Comscore

$1.28 /

-0.085 (-6.23%)

Meetings to be held on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SCOR Comscore
$1.28 /

-0.085 (-6.23%)

11/22/22
Beneficial owner of Comscore Cerberus Capital buys 75,629 shares of stock
09/29/22
Comscore to reduce workforce, sees $13M-$18M in related costs
09/22/22
Comscore, dentsu partner transact on advanced audiences in local TV
08/29/22
Comscore director buys $731K in common stock
SCOR Comscore
$1.28 /

-0.085 (-6.23%)

03/23/22 Craig-Hallum
ComScore poised for share gains in local measurement, says Craig-Hallum
03/01/22 Truist
Comscore price target lowered to $3.50 from $4 at Truist
SCOR Comscore
$1.28 /

-0.085 (-6.23%)

11/08/22
Comscore cuts 2022 revenue growth estimate to low single digits
11/08/22
Comscore reports Q3 EPS (60c), consensus (10c)
08/09/22
Comscore sees FY22 revenue up 5%-7% over 2021, consensus $393.42M
08/09/22
Comscore reports Q2 EPS (10c) vs (28c) last year
00:00 Today
Comscore
12/07/22
Comscore
12/08/22
Comscore
12/09/22
Comscore
Conference/Events
OmniAb to participate in a conference call with Benchmark » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
OABI

OmniAb

$3.91 /

-0.06 (-1.51%)

Healthcare Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

12/01/22
Hillstream BioPharma announces development of Knob Quatrabodies
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

11/04/22
Biotech Alert: Searches spiking for these stocks today
00:00 Today
OmniAb - OABI

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.